Semiology, proteomics, and the early detection of symptomatic cancer

Journal of Clinical Epidemiology

Volumn 56, Issue 9, 2003, Pages 815-819

  Porta, Miquel ^a,b,c   Fernandez, Esteve ^d,e   Alguacil, Joan ^a,f  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c IL   (United States)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Delay; Diagnosis; Genomics; Lung cancer; Proteomics; Semiology; Signs; Survival; Symptoms; Treatment

Indexed keywords

CANCER; CANCER CLASSIFICATION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL TYPE; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; GENE EXPRESSION; GENOMICS; HEALTH CARE SYSTEM; HUMAN; METHODOLOGY; ONCOGENE; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SOCIAL CLASS; SURVIVAL TIME; SYMPTOM; TUMOR GROWTH;

EID: 0141514713     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(03)00165-3     Document Type: Note

References (51)

1. Pita-Fernández S., Montero-Martinez C., Pértega-Diaz S., Verea-Hernando H. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. J Clin Epidemiol. 56:2003;820-825.
2. Fernandez E., Porta M., Malats N., Belloc J., Gallén M. Symptom to diagnosis interval and survival in cancers of the digestive tract. Dig Dis Sci. 47:2002;2434-2440.
3. Porta M., Fernandez E., Belloc J., Malats N., Gallén M., Alonso J. Emergency admission for cancer: a matter of survival? Br J Cancer. 77:1998;477-484.
4. Porta M., Gallén M., Belloc J., Malats N. Predictors of the interval between onset of symptoms and first medical visit in patients with digestive tract cancer. Int J Oncol. 8:1996;941-949.
5. Gómez G., Porta M., Griful E., et al. Modelling breast cancer survival and the symptom-to-treatment interval. J Epidemiol Biostat. 1:1996;175-182.
6. Maguire A., Porta M., Malats N., Gallén M., Piñol J.L. Fernandez E for the ISDS II Project Investigators. Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. Eur J Cancer. 30A:1994;785-792.
7. Porta M., Gallén M., Malats N., Planas J. The influence of "diagnostic delay" upon cancer survival. An analysis of five tumour sites. J Epidemiol Commun Health. 45:1991;225-230.
8. Feinstein A.R. Symptoms as an index of biological behaviour and prognosis in human cancer. Nature. 209:1966;241-245.
9. Charlson M.E., Feinstein A.R. The auxometric dimension. A new method for using rate of growth in prognostic staging of breast cancer. JAMA. 228:1974;180-185.
10. Feinstein A.R., Schimpff C.R., Andrews J.F. Jr., Wells C.K. Cancer of the larynx: a new staging system and a re-appraisal of prognosis and treatment. J Chron Dis. 30:1977;277-305.
11. Charlson M.E., Feinstein A.R. A new clinical index of growth rate in the staging of breast cancer. Am J Med. 69:1980;527-536.
12. Feinstein A.R., Wells C.K. Lung cancer staging. A critical evaluation. Clin Chest Med. 3:1982;291-305.
13. Wells C.K., Stoller J.K., Feinstein A.R., Horwitz R.I. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med. 144:1984;2004-2009.
14. Charlson M.E., Feinstein A.R. Rate of disease progression in breast cancer: a clinical estimate of prognosis within nodal and anatomic stages. J Natl Cancer Inst. 72:1984;225-231.
15. Piccirillo J.F., Feinstein A.R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 77:1996;834-842.
16. Yueh B., Feinstein A.R., Weaver E.M., Sasaki C.T., Concato J. Prognostic staging system for recurrent, persistent, and second primary cancers of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg. 124:1998;975-981.
17. Feinstein A.R. Is "quality of care" being mislabeled or mismeasured? Am J Med. 112:2002;472-478.
18. Pope C. Waiting times for outpatient appointments. BMJ. 306:1993;408-409.
19. Joint Council for Clinical Oncology. Reducing delays in cancer treatment. Some targets. 1993;Royal College of Physicians and Royal College of Radiologists, London.
20. Segnan N., Bugiani M., Ronco G., et al. The differential diagnosis of primary lung cancer: inter-observer agreement and contribution of specific diagnostic procedures. J Clin Epidemiol. 45:1992;827-833.
21. Malats N., Belloc J., Gallén M., Porta M. Disagreement between hospital medical records and a structured patient interview on the type and date of the first symptom in cancers of the digestive tract. Rev Epidemiol Sante Publique. 43:1995;533-540.
22. McDowell I., Newell C. Measuring health. A guide to rating scales and questionnaires. 1996;Oxford University Press, New York.
23. Feinstein A.R., Sosin D.M., Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 312:1985;1604-1608.
24. Porta M., Marrugat J., Pérez G. Trends in cardiovascular mortality and the quality of vital statistics. J Clin Epidemiol. 50:1997;221-222.
25. Greenberg E.R., Baron J.A., Dain B.J., Freeman D.H. Jr., Yates J.W., Korson R. Cancer staging may have different meanings in academic and community hospitals. J Clin Epidemiol. 44:1991;505-512.
26. Porta M., Piñol J.L., Maguire A., et al. Intertalacinoes entre el intervalo síntoma-diagnóstico y la supervivencia: ¿es possible obtener un estimador de la oportunidad ralativa del sesgo del Adelanto del diagnóstico clínico? Gac Sanit. 8:1994;68-69.
27. MacArthur C., Smith A. Factors associated with speed of diagnosis, referral, and treatment in colorectal cancer. J Epidemiol Commun Health. 38:1984;122-126.
28. Curless R., French J.M., Williams G.V., James O.F.W. Colorectal carcinoma: do elderly patients present differently? Age Ageing. 23:1994;102-107.
29. Swenson K.K., Rose M.A., Ritz L., Murray C.L., Adlis S.A. Recognition and evaluation of oncology-related symptoms in the emergency department. Ann Emerg Med. 26:1995;12-17.
30. Porta M., Malats N., Belloc J., Gallén M., Fernandez E. Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement. Eur J Epidemiol. 12:1996;553-562.
31. Fletcher R.H. CEA monitoring after surgery for colorectal cancer. When is the evidence sufficient? JAMA. 270:1993;987-988.
32. Delaloye A.B., Delaloye B. Radiolabelled monoclonal antibodies in tumor imaging and therapy: out of fashion? Eur J Nucl Med. 22:1995;571-580.
33. Ma P.C., Blaszkowsky L., Bharti A., et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 23:2003;49-62.
34. Duffy M.J., van Dalen A., Haglund C., et al. Clinical utility of biochemical markers in colorectal cancer. Eur J Cancer. 39:2003;718-727.
35. Frankel S., Smith G.D., Donovan J., Neal D. Screening for prostate cancer. Lancet. 361:2003;1122-1128.
36. Mulshine J.L., Henschke C.I. Prospects for lung-cancer screening. Lancet. 355:2000;592.
37. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
38. Petricoin E.F. 3rd, Hackett J.L., Lesko L.J., et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet. 32:(Suppl):2002;474-479.
39. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. Early detection: proteomic applications for the early detection of cancer. Natl Rev Cancer. 3:2003;267-275.
40. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet. 360:2002;169.
41. Bogardus S.T. Jr., Concato J., Feinstein A.R. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA. 281:1999;1919-1926.
42. Feinstein A.R. Misguided efforts and future challenges for research on "diagnostic tests." J Epidemiol Commun Health. 56:2002;330-332.
43. Feinstein A.R. Basic biomedical science and the destruction of the pathophysiologic bridge from bench to bedside. Am J Med. 107:1999;461-467.
44. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 17:1999;1794-1801.
45. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 19:2001;1734-1742.
46. Campbell D.E., Greenberg E.R. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 342:2000;517.
47. Cartman M.L., Hatfield A.C., Muers M.F., Peake M.D., Haward R.A., Forman D. Lung cancer: district active treatment rates affect survival. J Epidemiol Commun Health. 56:2002;424-429.
48. Earle C.C., Venditti L.N., Neumann P.J., et al. Who gets chemotherapy for metastatic lung cancer? Chest. 117:2000;1239-1246.
49. Greenwald H.P., Polissar N.L., Borgatta E.F., McCorkle R., Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health. 88:1998;1681-1684.
50. Husgafvel-Pursiainen K., Kannio A., Oksa P., et al. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen. 30:1997;224-230.
51. Kogevinas M., Porta M. Socioeconomic differences in cancer survival: a review of the evidence. Kogevinas M., Pearce N., Susser M., Boffetta P. Social inequalities and cancer. IARC Scientific Publications No. 138. 1997;177-206 International Agency for Research on Cancer, Lyon.